Abbott Laboratories (ABT) Competitors $123.81 +3.30 (+2.74%) Closing price 03:59 PM EasternExtended Trading$123.80 -0.01 (-0.01%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABT vs. DXCM, ISRG, TSLA, ABBV, BSX, ELV, ITGR, JNJ, MDT, and TMOShould you be buying Abbott Laboratories stock or one of its competitors? The main competitors of Abbott Laboratories include DexCom (DXCM), Intuitive Surgical (ISRG), Tesla (TSLA), AbbVie (ABBV), Boston Scientific (BSX), Elevance Health (ELV), Integer (ITGR), Johnson & Johnson (JNJ), Medtronic (MDT), and Thermo Fisher Scientific (TMO). Abbott Laboratories vs. Its Competitors DexCom Intuitive Surgical Tesla AbbVie Boston Scientific Elevance Health Integer Johnson & Johnson Medtronic Thermo Fisher Scientific Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Does the media refer more to ABT or DXCM? In the previous week, Abbott Laboratories had 96 more articles in the media than DexCom. MarketBeat recorded 113 mentions for Abbott Laboratories and 17 mentions for DexCom. DexCom's average media sentiment score of 1.36 beat Abbott Laboratories' score of 0.73 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 52 Very Positive mention(s) 13 Positive mention(s) 23 Neutral mention(s) 12 Negative mention(s) 3 Very Negative mention(s) Positive DexCom 12 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ABT or DXCM? Abbott Laboratories presently has a consensus target price of $144.47, suggesting a potential upside of 16.69%. DexCom has a consensus target price of $99.60, suggesting a potential upside of 18.73%. Given DexCom's stronger consensus rating and higher probable upside, analysts clearly believe DexCom is more favorable than Abbott Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abbott Laboratories 0 Sell rating(s) 5 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 2.82DexCom 0 Sell rating(s) 4 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 2.91 Is ABT or DXCM more profitable? Abbott Laboratories has a net margin of 32.43% compared to DexCom's net margin of 12.90%. DexCom's return on equity of 30.05% beat Abbott Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Abbott Laboratories32.43% 18.83% 10.88% DexCom 12.90%30.05%10.00% Which has more risk & volatility, ABT or DXCM? Abbott Laboratories has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Do insiders & institutionals believe in ABT or DXCM? 75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings & valuation, ABT or DXCM? Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbott Laboratories$41.95B5.13$13.40B$7.7116.06DexCom$4.03B8.16$576.20M$1.3462.60 SummaryDexCom beats Abbott Laboratories on 9 of the 16 factors compared between the two stocks. Get Abbott Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABT vs. The Competition Export to ExcelMetricAbbott LaboratoriesMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$209.67B$10.12B$5.52B$20.73BDividend Yield1.96%2.05%3.80%3.69%P/E Ratio15.5216.5928.0427.57Price / Sales5.1329.60429.5359.01Price / Cash18.3122.2635.8422.13Price / Book4.483.578.124.66Net Income$13.40B$235.43M$3.25B$994.58M7 Day Performance-6.17%-1.67%0.97%-0.29%1 Month Performance-6.45%2.91%7.36%4.91%1 Year Performance23.70%-16.44%31.31%10.53% Abbott Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABTAbbott Laboratories4.988 of 5 stars$123.81+2.7%$144.47+16.7%+15.3%$209.67B$41.95B15.52114,000Trending NewsEarnings ReportEx-DividendAnalyst ForecastHigh Trading VolumeDXCMDexCom4.7868 of 5 stars$85.21+2.2%$98.50+15.6%-26.6%$33.35B$4.15B63.4810,300Positive NewsAnalyst ForecastISRGIntuitive Surgical4.7015 of 5 stars$518.99+1.4%$592.86+14.2%+21.1%$185.95B$8.35B76.0715,638Positive NewsUpcoming EarningsAnalyst RevisionTSLATesla4.6873 of 5 stars$316.02+0.8%$300.19-5.0%+28.5%$1.02T$97.69B173.42125,665Trending NewsUpcoming EarningsABBVAbbVie4.7844 of 5 stars$191.06-0.7%$211.29+10.6%+9.1%$337.24B$56.33B81.2455,000Trending NewsEx-DividendAnalyst RevisionBSXBoston Scientific4.6219 of 5 stars$104.48+1.2%$116.09+11.1%+35.1%$154.46B$16.75B76.2153,000Trending NewsUpcoming EarningsELVElevance Health4.9753 of 5 stars$339.25-0.4%$491.07+44.7%-42.1%$76.71B$177.01B13.25104,200Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastInsider TradeGap DownITGRInteger3.8897 of 5 stars$119.01-0.8%$145.00+21.8%-7.7%$4.15B$1.72B56.3811,000News CoveragePositive NewsUpcoming EarningsJNJJohnson & Johnson4.7823 of 5 stars$156.56-0.2%$171.00+9.2%+4.1%$376.50B$89.33B17.41138,100Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastOptions VolumeAnalyst RevisionMDTMedtronic4.6379 of 5 stars$89.56-0.4%$97.47+8.8%+10.2%$114.88B$33.54B24.7495,000Positive NewsAnalyst ForecastAnalyst RevisionTMOThermo Fisher Scientific4.9933 of 5 stars$427.00-1.8%$600.30+40.6%-23.4%$161.19B$42.90B25.04125,000Trending NewsUpcoming EarningsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies DXCM Alternatives ISRG Alternatives TSLA Alternatives ABBV Alternatives BSX Alternatives ELV Alternatives ITGR Alternatives JNJ Alternatives MDT Alternatives TMO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ABT) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abbott Laboratories Please log in to your account or sign up in order to add this asset to your watchlist. Share Abbott Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.